Literature DB >> 23851493

The immune network in pancreatic cancer development and progression.

S M Wörmann1, K N Diakopoulos1, M Lesina1, H Algül1.   

Abstract

The presence of stromal desmoplasia is a hallmark of spontaneous pancreatic ductal adenocarcinoma, forming a unique microenvironment that comprises many cell types. Only recently, the immune system has entered the pathophysiology of pancreatic ductal adenocarcinoma development. Tumor cells in the pancreas seem to dysbalance the immune system, thus facilitating spontaneous cancer development. This review will try to assemble all relevant data to demonstrate the implications of the immune network on spontaneous cancer development.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23851493     DOI： 10.1038/onc.2013.257

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  82 in total

1.  Pancreatic Cancer: a Challenge to Cure.

Authors:  M Tewari
Journal:  Indian J Surg       Date:  2015-10-19       Impact factor: 0.656

2.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

Review 3.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

4.  Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.

Authors:  Li Wenbo; Jin Wang
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

Review 5.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Authors:  Ignacio Garrido-Laguna; Manuel Hidalgo
Journal:  Nat Rev Clin Oncol       Date:  2015-03-31       Impact factor: 66.675

6.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Authors:  Herbert I Hurwitz; Nikhil Uppal; Stephanie A Wagner; Johanna C Bendell; J Thaddeus Beck; Seaborn M Wade; John J Nemunaitis; Philip J Stella; J Marc Pipas; Zev A Wainberg; Robert Manges; William M Garrett; Deborah S Hunter; Jason Clark; Lance Leopold; Victor Sandor; Richard S Levy
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

7.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

Authors:  Svetlana Karakhanova; Julia Link; Moritz Heinrich; Ivan Shevchenko; Yuhui Yang; Matthias Hassenpflug; Henriette Bunge; Katharina von Ahn; Ramona Brecht; Andreas Mathes; Caroline Maier; Viktor Umansky; Jens Werner; Alexandr V Bazhin
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

8.  IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Authors:  Bhalchandra Mirlekar; Daniel Michaud; Ryan Searcy; Kevin Greene; Yuliya Pylayeva-Gupta
Journal:  Cancer Immunol Res       Date:  2018-07-06       Impact factor: 11.151

Review 9.  Functional genomics: paving the way for more successful cancer immunotherapy.

Authors:  Reham Ajina; Danielle Zamalin; Louis M Weiner
Journal:  Brief Funct Genomics       Date:  2019-03-22       Impact factor: 4.241

Review 10.  Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Authors:  Alessandro Paniccia; Justin Merkow; Barish H Edil; Yuwen Zhu
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.